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Tumor hypoxia is thought to be primarily caused by
deficiencies in the tumor blood supply. Solid tumors of-
ten have large areas of both chronic and acute hypoxia.
Overwhelming clinical and experimental data indicate
that tumor hypoxia is associated with aggressive dis-
ease and poor treatment outcomes for radiotherapy
and chemotherapy [1–6]. Thus, the hypoxic fraction of
individual tumors before, during and after therapy is
likely to have prognostic value.
Several methods for evaluating tumor hypoxia,
both invasively and noninvasively, have been exam-
ined. An invasive technique using oxygen-sensitive
electrodes that measures oxygen partial pressure (pO2)
distributions in the tumor tissue has shown that hyp-
oxic tumors respond poorly to radiation therapy [1–3].
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Hypoxic cells within a tumor can account, in part, for resistance to radiotherapy and chemotherapy.
Indeed, the oxygenation status has been shown to be a prognostic marker for the outcome of
therapy. The purpose of this study was to determine whether Tc-99m HL91 (HL91), a noninva-
sive imaging tracer, detects tumor hypoxia in vitro in cell culture and in vivo in a tumor model.
Uptake of HL91 in vitro into human lung cancer cells (A549) and murine Lewis lung cancer cells
(LL2) was investigated at oxygen concentrations of 20% O2 (normoxia), and 1% O2 (hypoxia).
HL91 biodistribution was studied in four groups: severe combined immune deficiency (SCID)
mice bearing A549 tumors, C57BL/6NCrj (B6) mice bearing LL2 tumors, SCID controls, and B6
controls. Accumulation of the tracer was compared between tumors treated with hydralazine or
phosphate-buffered saline (PBS). Scintigraphic images were obtained for hydralazine-treated
mice and PBS-treated mice in each of the four study groups. Autoradiography of tumor slices was
also acquired. In vitro studies identified hypoxia-selective uptake of HL91, with significantly in-
creased uptake in the hypoxic state than in the normoxic state. Biodistribution and scintigraphy
showed increased HL91 uptake during tumor hypoxia at 0.5 hours, and there was progressively
increased activity for up to 4 hours after tracer administration. HL91 accumulation in tumor
hypoxia was markedly increased in mice treated with hydralazine compared with those treated
with PBS. Autoradiography revealed high HL91 uptake in the peripheral areas around the
necrotic regions of the tumor, which were identified by histologic examination. HL91 exhibits
selectivity for tumor hypoxia both in vitro and in vivo and provides a successful imaging modality
for the detection of tumor hypoxia in vivo.
Key Words: in vitro, in vivo, scintigraphy, Tc-99m HL91, tumor hypoxia
(Kaohsiung J Med Sci 2008;24:461–72)
Kaohsiung J Med Sci September 2008 • Vol 24 • No 9462
B.F. Lee, N.T. Chiu, C.C. Hsia, and L.H. Shen
However, the development of a noninvasive, routine
detection of tumor hypoxia to identify patients in need
of more aggressive therapy is needed. Noninvasive
methods such as magnetic resonance spectroscopy [5]
and imaging of radiolabeled compounds that are selec-
tively retained in regions of hypoxia [6–30] have been
studied.
Detection of tumor hypoxia by a radionuclide imag-
ing technique was first proposed by Chapman et al,
who used radiolabeled 2-nitroimidazoles [6]. I-123
iodoazomycin arabinoside (IAZA) accumulated selec-
tively in regions of tumor hypoxia [11]. Tc-99m-labeled
ligands containing 2-nitroimidazole, including BMS
181321, and BRU59-21, displayed selectivity for tissues
with hypoxia [12,13]. Butyleneamine oxime (BnAO,
HL91) is another Tc-99m complex and has shown
even greater selectivity for hypoxia in tumor hypoxia
[14–23], ischemic myocardium [25–29] and cerebral is-
chemia [30]. In assessing treatment responses, a highly
significant correlation was found between tumor up-
take of HL91 and antitumor response to antivascular
agents [18]. The mechanism of HL91 localization is not
well understood. It was reported that the intrinsic prop-
erties of Tc-99m complexes are predominantly respon-
sible for the selectivity for regions with hypoxia [16].
Animal tumor models of a human lung cancer cell
line (A549) and a murine lung cancer cell line (LL2)
have been established. Both of these tumor models
are known to contain hypoxic cells. HL91 uptake was
compared between these two species in vitro and 
in vivo. The aim of this study was to determine whether
HL91 identifies the presence of hypoxic cells in vitro
and hypoxic tissues in vivo, and to measure the uptake
of HL91 by imaging tumor hypoxia.
MATERIALS AND METHODS
Radiolabeled tracer
Lyophilized HL91 kits were prepared by the Institute
of Nuclear Energy Research, Lungtan, Taiwan. Each
HL91 kit contained 200 μg of HL91 ligand, 20 μg of
stannous chloride dihydrate, 40 μg of methylene di-
phosphonic acid and buffer salts, in a 10 mL glass vial
sealed under nitrogen atmosphere. Tc-99m-HL91 was
prepared by reconstitution of an HL91 kit into 4.5 mL
of a solution containing 900 MBq (24.3 mCi) of Tc-99m-
sodium pertechnetate in accordance with the manu-
facturer’s instructions. The radiochemical purity
determined by thin layer chromatography was typi-
cally > 98%.
Uptake of Tc-99m HL91 into cells
The apparatus and procedures for the in vitro experi-
ments are based on methods previously described
[19]. Viability of cells was measured with a hemocy-
tometer based on trypan blue exclusion. A549 and
LL2 cancer cells (1.2 × 106 cells/mL; American Type
Culture Collection, Manassas, VA, USA) were sepa-
rately cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with gentamicin (50 μg/mL),
2 mm L-glutamine, and 10% heat-inactivated fetal
bovine serum at 37°C in 5% CO2. A continual flow of
warmed, humidified gas (20% O2, 5% CO2, 75% N2
[normoxia], or 1% O2, 5% CO2, 94% N2 [hypoxia])
was passed over the cells. pO2 values were monitored
by an oxygen analyzer within an automated value
system (Pro-Ox, BioSpherix Ltd., Redfield, NY, USA).
After equilibration of the humidified gas for 24 hours,
7.4 MBq HL91 was added to the cells. At 0.5, 1, 2, 3
and 4 hours after incubation with HL91, the media
were removed. Cells were washed with phosphate-
buffered saline (PBS). Cell suspensions were then cen-
trifuged at 400g for 5 minutes, followed by aspiration
of the supernatant. Radioactivity in the cell pellets
was measured with a gamma counter (Cobra II, Pack-
ard Instrument Company, Meriden, CT, USA). Wells
containing the culture medium without cells were
similarly treated to assess absorbance of nonspecific
radioactivity by the tubes. Experiments were per-
formed twice to confirm the reproducibility of the
results. The percentage uptake of the tracer into the
cells was calculated.
Animal tumor models and biodistribution
studies
All animal experiments were conducted in compli-
ance with the Guidelines for the Care and Use of 
Research Animals established by National Cheng-
Kung University’s Animal Studies Committee. Severe
combined immune deficiency (SCID) mice and C57BL/
6NCrj (B6) mice were implanted subcutaneously into
the right hind leg with A549 or LL2 cells (5 ×
105 cells/mL). A total of 204 mice were grouped into
A549 tumors (n = 66), LL2 tumors (n = 66), SCID con-
trols (n = 36) or B6 controls (n = 36). HL91 (7.4 MBq)
was injected into the tail vein and the animals were
killed at 0.5, 1, 2, 3 or 4 hours post-injection. Selected
tissues and organs were harvested and weighed, and
the radioactivity counted on a gamma counter. The
percentage injected dose per gram (%ID/g) for each
tissue was calculated.
Tumor oxygenation was chemically reduced by
hydralazine [19,24]. Hydralazine (5 mg/kg) dissolved
in 0.1 mL of saline was intraperitoneally administered
30 minutes prior to tracer injection. PBS-treated mice
were injected with 0.1mL of PBS. Each group consisted
of six mice. Selected tissues and organs were removed
from the animals at 2 and 4 hours post administra-
tion of HL91 (7.4 MBq). The %ID/g of each tissue was
acquired.
Scintigraphic examination and image
analysis
All six groups included SCID controls, B6 controls,
PBS-treated A549 tumors, PBS-treated LL2 tumors,
hydralazine-treated A549 tumors, and hydralazine-
treated LL2 tumors (n=6/group). Scintigraphic images
were obtained at 0.5, 1, 2 and 4 hours after HL91
(37 MBq; 1 mCi) injection and were acquired with a
gamma camera (Diacam, Siemens, Hoffman Estates,
IN, USA) equipped with a low energy, high-resolution
collimator. Tumor hypoxia was quantified by methods
for defining regions of interest (ROI). The reference
tissue was selected in the contralateral hind leg of the
same mice. Tumor uptake ratios [ROI tumor/(ROI
tumor + ROI contralateral)] were calculated.
Autoradiography and H&E staining
Animals bearing A549 and LL2 tumors were injected
with 37 MBq (1 mCi) HL91 through the caudal vein
and killed 2 hours after the injection. Tumors were
removed and immediately frozen with liquid nitro-
gen. The frozen tumors were then embedded with
O.C.T compound (Miles Inc., Elkhart, IN, USA) and
cut into 10-μm-thick sections with a cryomicrotome
(Bright OTF, Bright Instrument Company Ltd.,
Huntingdon, England). Frozen sections were applied
to a phosphor imaging plate and exposed overnight.
The distribution of radioactivity was estimated quali-
tatively by comparing the degree of darkening on
each phosphor Imager (FLA5000, Fuji Photo Film Co.,
Tokyo, Japan). Darker gray levels represent greater
concentrations of radioactivity. The other continuous
sections that were mounted on clean slides were stain-
ed with hematoxylin and eosin (H&E) and examined
under a light microscope.
Statistical analysis
Results are expressed as mean ± standard deviation.
Statistical comparisons were done using Student’s t test,
assuming a significance level of 0.05.
RESULTS
Uptake of Tc-99m HL91 into cells
Hypoxic conditions significantly increased HL91
uptake into cells compared with normoxic conditions
in both A549 (Figure 1A) and LL2 cells (Figure 1B). 
In A549 cells, HL91 uptake was increased by approx-
imately 4–9-fold by hypoxia compared with normoxia
(Figure 1A). Hypoxia had a greater effect in LL2 cells,
increasing HL91 uptake by 10–16-fold (Figure 1B).
Tc-99m HL91: in vitro and in vivo study
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Figure 1. Cellular uptake of Tc-99m HL91 in: (A) A549 human lung cancer cells; (B) Lewis lung (LL2) murine cancer cells. Tracer uptake
studies were conducted twice; one set of data is presented as a representative example. Bars indicate standard deviation. *p < 0.05.
Animal biodistribution studies
The biodistribution of HL91 in SCID controls (Table 1)
was determined at 0.5, 1, 2, 3 and 4 hours after 
HL-91 injection. The liver retained the highest con-
centrations of HL-91 (range, 8.75 ± 2.67 to 9.13 ±
2.91 %ID/g). The lowest concentration was in the
brain (range, 0.07 ± 0.01 to 0.08 ± 0.01 %ID/g). Inter-
mediate levels were found in the bowel, stomach,
spleen, kidney, lung, heart, bone and muscle. A simi-
lar biodistribution of HL91 was seen in normal B6
mice (Table 2).
For mice bearing A549 tumors (Table 3) and LL2
tumors (Table 4), the results of the biodistribution
study showed that the liver had the highest concen-
trations and the brain the lowest. The intermediate
levels in bowel, stomach, spleen, kidney, lung, heart,
bone and muscle are shown. There was little appar-
ent difference in the biodistribution between non-
tumor and tumor-bearing mice.
The presence of hydralazine significantly affected
HL biodistribution within A549 tumors (Table 5).
Hydralazine resulted in selective and statistically 
significant increases in HL91 uptake. There was 
no statistically significant change in retention of
HL91 in normal tissues after hydralazine injection,
with the exception of a 59% increment at 2 hours 
and a 28% increment at 4 hours in the liver after
administration of hydralazine. There were similar
findings for the biodistribution in LL2 tumors 
(Table 6).
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Table 1. Biodistribution of Tc-99m HL91 in normal SCID mice (n = 6)*
Tissue
% injected dose/g
0.5 hr 1 hr 2 hr 3 hr 4 hr
Blood 26.52 ± 11.78 12.48 ± 6.91 6.05 ± 2.89 1.23 ± 0.87 0.39 ± 0.05
Urine 11.63 ± 3.21 18.57 ± 6.77 20.65 ± 11.70 31.13 ± 13.95 42.73 ± 18.21
Bowel 0.33 ± 0.09 0.32 ± 0.17 0.34 ± 0.12 0.36 ± 0.18 0.34 ± 0.13
Stomach 0.92 ± 0.49 0.87 ± 0.37 0.83 ± 0.27 0.89 ± 0.34 0.94 ± 0.33
Spleen 0.60 ± 0.28 0.76 ± 0.27 0.62 ± 0.30 0.79 ± 0.33 0.74 ± 0.29
Liver 8.75 ± 2.67 8.86 ± 3.02 9.08 ± 2.77 9.13 ± 2.91 8.82 ± 3.33
Kidney 2.61 ± 1.09 2.86 ± 1.20 1.25 ± 0.66 1.68 ± 0.31 1.47 ± 0.27
Lung 0.12 ± 0.04 0.16 ± 0.09 0.09 ± 0.03 0.09 ± 0.02 0.10 ± 0.03
Heart 0.68 ± 0.21 0.76 ± 0.17 0.53 ± 0.21 0.35 ± 0.11 0.30 ± 0.13
Brain 0.08 ± 0.01 0.08 ± 0.01 0.07 ± 0.01 0.08 ± 0.01 0.07 ± 0.01
Bone 0.41 ± 0.11 0.42 ± 0.22 0.34 ± 0.11 0.25 ± 0.09 0.15 ± 0.09
Muscle 0.12 ± 0.09 0.14 ± 0.08 0.11 ± 0.03 0.15 ± 0.07 0.15 ± 0.07
*Data are presented as mean ± standard deviation.
Table 2. Biodistribution of Tc-99m HL91 in normal C57BL/6NCrj (B6) mice (n = 6)*
Tissue
% injected dose/g organ
0.5 hr 1 hr 2 hr 3 hr 4 hr
Blood 14.76 ± 0.04 3.30 ± 0.07 1.40 ± 0.02 0.12 ± 0.05 0.07 ± 0.05
Urine 13.70 ± 1.14 14.14 ± 1.40 16.82 ± 1.29 27.94 ± 0.60 39.48 ± 0.11
Bowel 0.55 ± 0.08 2.83 ± 0.60 1.85 ± 0.31 1.92 ± 0.15 0.84 ± 0.13
Stomach 0.56 ± 0.05 0.62 ± 0.37 0.55 ± 0.06 0.71 ± 0.34 0.63 ± 0.05
Spleen 0.47 ± 0.07 0.55 ± 0.02 0.45 ± 0.10 0.44 ± 0.13 0.48 ± 0.05
Liver 0.83 ± 0.06 1.01 ± 0.16 1.12 ± 0.16 1.14 ± 0.05 1.23 ± 0.01
Kidney 1.63 ± 0.07 2.79 ± 0.04 2.82 ± 0.05 3.30 ± 0.09 3.36 ± 0.27
Lung 0.42 ± 0.02 0.42 ± 0.09 0.30 ± 0.08 0.31 ± 0.12 0.23 ± 0.06
Heart 0.28 ± 0.05 0.32 ± 0.09 0.13 ± 0.03 0.16 ± 0.06 0.13 ± 0.13
Brain 0.04 ± 0.01 0.07 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.05 ± 0.01
Bone 0.21 ± 0.08 0.38 ± 0.10 0.28 ± 0.11 0.15 ± 0.09 0.14 ± 0.15
Muscle 0.44 ± 0.15 0.23 ± 0.08 0.16 ± 0.04 0.11 ± 0.04 0.12 ± 0.04
*Data are presented as mean ± standard deviation.
Scintigraphic examination and image
analysis
Figure 2 shows scintigraphic images of normal SCID
(Figure 2A) and B6 mice (Figure 2C). There was an
apparent accumulation of the radiotracer over the
abdomen. In all of the mice bearing tumors, HL91
was retained in the tumors over the course of imag-
ing up to 4 hours. Accumulation of the tracer in A549
(Figure 3) and LL2 (Figure 4) tumors was markedly
increased in hydralazine-treated mice compared
with PBS-treated mice. When HL91 uptake was com-
pared using ROIs placed on scintigrams between
hydralazine- and PBS-treated mice, A549 tumor
uptake was increased by 3.75%, 7.41%, 10.98% and
13.58% relative to that of PBS-treated mice at 0.5, 1, 2
and 4 hours, respectively. Similarly, LL2 tumor accu-
mulation of HL91 was increased by 13.34%, 14.82%,
31.06% and 29.08% at 0.5, 1, 2 and 4 hours, respec-
tively (Figure 5).
Autoradiography and HE staining
The autoradiograms obtained from tumor samples
revealed the highest apparent accumulation of
radioactivity in the periphery of the A549 (Figure 6A)
and LL2 tumors (Figure 6D). The regions with low
HL91 uptake corresponded to histologically necrotic
areas, as shown by H&E staining (Figures 6D and 6F).
The fused images (Figures 6B and 6E) from the
Tc-99m HL91: in vitro and in vivo study
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Table 4. Biodistribution of Tc-99m HL91 in B6 mice bearing LL2 tumors (n = 6)*
Tissue
% injected dose/g organ
0.5 hr 1 hr 2 hr 3 hr 4 hr
Blood 16.43 ± 1.08 2.30 ± 1.01 1.28 ± 1.02 0.40 ± 0.19 0.24 ± 0.14
Urine 16.80 ± 5.68 18.20 ± 9.58 28.45 ± 12.89 48.90 ± 10.88 62.11 ± 10.21
Bowel 4.83 ± 3.21 8.21 ± 3.39 9.07 ± 4.66 7.68 ± 4.98 12.97 ± 3.87
Stomach 3.61 ± 1.02 4.02 ± 1.03 6.80 ± 1.38 2.18 ± 0.84 0.87 ± 0.29
Spleen 0.91 ± 0.22 1.46 ± 0.36 2.40 ± 0.33 0.89 ± 0.23 0.43 ± 0.48
Liver 5.99 ± 1.97 11.28 ± 2.58 14.41 ± 3.11 18.34 ± 2.11 15.15 ± 1.25
Kidney 1.72 ± 1.54 3.10 ± 1.96 4.95 ± 2.04 3.98 ± 1.87 3.63 ± 1.44
Lung 1.46 ± 1.02 1.59 ± 1.08 1.53 ± 0.91 0.89 ± 0.24 0.46 ± 0.14
Heart 0.94 ± 0.22 0.78 ± 0.17 0.94 ± 0.20 0.42 ± 0.15 0.23 ± 0.11
Tumor 1.06 ± 0.27 1.18 ± 0.23 2.05 ± 0.54 2.25 ± 0.67 2.49 ± 0.88
Brain 0.02 ± 0.01 0.24 ± 0.02 0.24 ± 0.01 0.16 ± 0.03 0.07 ± 0.02
Bone 0.66 ± 0.24 0.88 ± 0.21 1.72 ± 0.34 0.38 ± 0.13 0.18 ± 0.09
Muscle 0.30 ± 0.10 0.83 ± 0.24 2.52 ± 0.69 0.36 ± 0.17 0.12 ± 0.11
*Data are presented as mean ± standard deviation.
Table 3. Biodistribution of Tc-99m HL91 in SCID mice bearing A549 tumors (n = 6)*
Tissue
% injected dose/g
0.5 hr 1 hr 2 hr 3 hr 4 hr
Blood 30.33 ± 14.21 13.75 ± 4.44 6.56 ± 3.21 1.77 ± 0.19 0.31 ± 0.19
Urine 11.28 ± 5.68 14.77 ± 9.58 18.32 ± 12.89 31.93 ± 13.89 50.20 ± 22.91
Bowel 0.46 ± 0.12 0.43 ± 0.12 0.32 ± 0.13 0.23 ± 0.12 0.20 ± 0.08
Stomach 0.90 ± 0.31 0.91 ± 0.27 0.91 ± 0.23 0.96 ± 0.37 0.99 ± 0.29
Spleen 0.40 ± 0.22 0.81 ± 0.36 0.76 ± 0.33 0.92 ± 0.42 0.97 ± 0.39
Liver 10.45 ± 3.41 9.56 ± 3.46 5.90 ± 2.99 8.62 ± 2.89 8.37 ± 3.11
Kidney 4.71 ± 1.54 4.21 ± 1.96 4.40 ± 2.11 1.83 ± 0.99 3.17 ± 1.44
Lung 0.12 ± 0.09 0.13 ± 0.06 0.15 ± 0.09 0.09 ± 0.03 0.09 ± 0.03
Heart 0.43 ± 0.22 0.44 ± 0.17 0.59 ± 0.21 0.51 ± 0.15 0.53 ± 0.21
Tumor 1.77 ± 1.01 1.78 ± 0.89 1.96 ± 0.54 2.36 ± 1.03 2.57 ± 1.01
Brain 0.04 ± 0.01 0.02 ± 0.02 0.03 ± 0.01 0.05 ± 0.03 0.05 ± 0.02
Bone 0.45 ± 0.24 0.35 ± 0.19 0.42 ± 0.34 0.30 ± 0.22 0.38 ± 0.13
Muscle 0.24 ± 0.13 0.21 ± 0.08 0.26 ± 0.11 0.24 ± 0.17 0.25 ± 0.10
*Data are presented as mean ± standard deviation.
autoradiography and H&E staining provided clear
visual evidence for the preferential uptake of HL91 in
the border zone.
DISCUSSION
Our study has revealed that HL91 shows good selec-
tivity for hypoxic regions in vitro and in vivo. The per-
centage uptake of HL91 into A549 and LL2 cells in vitro
was significantly increased under hypoxic conditions
compared with normoxic conditions throughout the
4-hour study (Figure 1). There was no significant dif-
ference between human lung cancer cells and murine
lung cancer cells.
Hydralazine, which belongs to the antihyperten-
sive class of medicines, has been shown to cause
decreased blood flow to tumors that results in de-
creased oxygen concentrations within the implanted
tumors [19,24]. Therefore, hydralazine was used to
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Table 5. Biodistribution of Tc-99m HL91 in hydralazine-treated mice bearing A549 tumors compared with 
PBS-treated mice*
% injected dose/g
Tissue PBS-treated mice (n = 6) Hydralazine-treated mice (n = 6)
2 hr 4 hr 2 hr 4 hr
Blood 6.56 ± 3.21† 0.31 ± 0.19† 2.34 ± 1.11† 1.10 ± 1.06†
Urine 18.32 ± 12.89† 50.20 ± 22.91† 8.21 ± 3.76† 25.19 ± 14.27†
Bowel 0.32 ± 0.13 0.20 ± 0.08 0.30 ± 0.13 0.28 ± 0.11
Stomach 0.91 ± 0.23 0.99 ± 0.29 0.76 ± 0.31 0.69 ± 0.13
Spleen 0.76 ± 0.33 0.97 ± 0.39 0.90 ± 0.21 0.93 ± 0.99
Liver 5.90 ± 2.99† 8.37 ± 3.11† 9.42 ± 3.89† 10.80 ± 2.87†
Kidney 4.40 ± 2.11 3.17 ± 1.44 3.34 ± 1.95 3.49 ± 2.12
Lung 0.15 ± 0.09 0.09 ± 0.03 0.12 ± 0.04 0.10 ± 0.19
Heart 0.59 ± 0.21 0.53 ± 0.21 0.54 ± 0.22 0.59 ± 0.08
Tumor 1.96 ± 0.54† 2.57 ± 1.01† 3.08 ± 2.01† 4.66 ± 2.29†
Brain 0.03 ± 0.01 0.05 ± 0.02 0.03 ± 0.01 0.03 ± 0.02
Bone 0.42 ± 0.34 0.38 ± 0.13 0.47 ± 0.19 0.42 ± 0.19
Muscle 0.26 ± 0.11 0.25 ± 0.10 0.21 ± 0.11 0.23 ± 0.11
*Data are presented as mean ± standard deviation; †p < 0.05 between hydralazine-treated mice and PBS-treated mice (Student’s t test).
Table 6. Biodistribution of Tc-99m HL91 in hydralazine-treated mice bearing LL2 tumors in comparison with 
PBS-treated animals*
% injected dose/g
Tissue PBS-treated mice (n = 6) Hydralazine-treated mice (n = 6)
2 hr 4 hr 2 hr 4 hr
Blood 1.28 ± 1.02† 0.24 ± 0.14† 5.60 ± 1.12† 2.72 ± 1.06†
Urine 21.87 ± 12.89† 40.97 ± 10.21† 27.78 ± 10.88† 55.76 ± 14.27†
Bowel 0.35 ± 0.47 0.43 ± 0.19 0.38 ± 0.13 0.30 ± 0.11
Stomach 0.68 ± 0.23 0.87 ± 0.29 0.42 ± 0.21 0.37 ± 0.13
Spleen 0.80 ± 0.33 0.43 ± 0.24 0.39 ± 0.19 0.34 ± 0.99
Liver 14.41 ± 3.11† 5.15 ± 1.25† 16.53 ± 4.22† 7.41 ± 2.87†
Kidney 4.95 ± 2.04 3.63 ± 1.44 5.48 ± 2.11 4.57 ± 2.12
Lung 0.51 ± 0.91 0.46 ± 0.14 0.49 ± 0.20 0.40 ± 0.19
Heart 0.94 ± 0.20 0.23 ± 0.11 0.21 ± 0.09 0.16 ± 0.08
Tumor 2.05 ± 0.54† 2.49 ± 0.88† 3.93 ± 1.89† 5.11 ± 2.29†
Brain 0.24 ± 0.01 0.07 ± 0.02 0.23 ± 0.11 0.19 ± 0.09
Bone 0.57 ± 0.34 0.18 ± 0.09 0.54 ± 0.23 0.39 ± 0.2
Muscle 0.63 ± 0.23 0.51 ± 0.06 0.50 ± 0.19 0.34 ± 0.22
*Data are presented as mean ± standard deviation; †p < 0.05 between hydralazine-treated mice and PBS-treated mice (Student’s t test).
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Figure 2. (A, C) Tc-99m HL91 scintigraphy shows the normal distribution of radiotracer accumulation over the whole body of control
mice. Also shown are photos of: (B) SCID mouse; (D) B6 mouse.
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Figure 3. In representative 12-week-old SCID mice with A549 tumors, Tc-99m HL91 scintigraphy (left panel: PBS-treated mouse;
right panel: hydralazine-treated mouse) at: (A) 0.5 hours; (B) 1 hour; (C) 2 hours; and (D) 4 hours reveals increased radiotracer accu-
mulation over the tumors (arrows). The tumor uptake ratios are: (A) 80.23%; (B) 81.38%; (C) 82.42%; and (D) 81.74% for the PBS-treated
mouse (left panel). The tumor uptake ratios are: (A) 83.47%; (B) 87.12%; (C) 91.23%; and (D) 92.32% for the hydralazine-treated
mouse (right panel).
chemically reduce tumor oxygenation. Tables 5 and 6
revealed that hydralazine-treated mice had greater
HL91 uptake compared with PBS-treated mice for both
A549 and LL2 tumors. Our findings are consistent with
those of Kinuya et al [19]. No significant difference
between A549 and LL2 tumors was found, but there
was a significant difference between hydralazine-treated
and PBS-treated tumors.
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Figure 4. This is a representative image of a 12-week-old mouse with LL2 tumors. Tc-99m HL91 scintigraphy (left panel: PBS-treated
mouse; right panel: hydralazine-treated mouse) at: (A) 0.5 hours; (B) 1 hour; (C) 2 hours; and (D) 4 hours reveals increased radiotracer
accumulation over the tumors (arrows). The tumor uptake ratios are: (A) 71.31%; (B) 74.41%; (C) 68.24%; and (D) 68.39% for the
PBS-treated mouse (left panel). The tumor uptake ratios are: (A) 80.34%; (B) 85.78%; (C) 89.97%; and (D) 88.99% for the
hydralazine-treated mouse (right panel).
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Figure 5. Tumor uptake of Tc-99m HL91 by: (A) A549 human lung cancer cells, and (B) Lewis lung (LL2) murine cancer cells were
calculated by ROI analysis of scintigraphic images. Hydralazine-treated mice had significantly increased tumor uptake compared with
PBS-treated mice (p < 0.05).
All scintigrams of normal mice (Figure 2) and of
mice bearing tumors (Figures 3 and 4) showed high
levels of radioactivity accumulation in the abdomen.
According to the biodistribution results (Tables 1–6),
abdominal uptake was mostly secondary to the
radiotracer accumulation over the liver and bilateral
kidneys. Little radioactivity was identified in the brain,
lung, bone or muscle (Figures 2–4). Visually, the
hydralazine-treated mice showed higher tumor uptake
of HL91 than did PBS-treated mice (Figures 3–5).
Both autoradiograms and H&E staining of tumor
sections (Figure 6) indicated low uptake of HL91 in
necrotic areas and enhanced tracer uptake in the bor-
der zone, suggesting that this is a hypoxic region.
Our results showed that HL91 uptake was lower in
necrotic areas than in viable regions; hence, HL91 can
distinguish oxidation status in tumor tissues. This
result is consistent with the findings that HL91 was
observed in the hypoxic zone [14].
Our results show that HL91 imaging can non-
invasively visualize and quantify tumor hypoxia in
individual tumors. For both in vitro and in vivo evalu-
ations, there was a several-fold higher accumulation
of HL91 in tumor hypoxia. Our data suggest that
HL91 imaging is feasible and provides adequate
image quality. Future studies will address the use of
this hypoxia imaging agent not only to clinically
assess tumor hypoxia, but also to monitor the effec-
tiveness of various strategies known to overcome
hypoxia. Additional studies are now needed to deter-
mine whether assessment of tumor hypoxia with
HL91 provides information about tumor behavior
that cannot be obtained with conventional prognostic
indicators.
Our autoradiographic data clearly support our 
in vitro results, biodistribution and scintigraphy. These
results confirm the selectivity of HL91 for hypoxic
tissues. Moreover, HL91 imaging can noninvasively
visualize and semi-quantify the extent and spatial
distribution of tumor hypoxia for individual tumors
in living mice. Our data indicate the usefulness of
this tracer as a hypoxia imaging agent.
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Figure 6. Autoradiographic studies of Tc-99m HL91 distribution in: (A, B, C) A549, and (D, E, F) LL2 tumor sections revealed 
the highest apparent accumulation of radioactivity at the periphery of the necrosis, which was identified by histologic examination. 
A and D are autoradiograms; B and E are fused imaging of autoradiograms and H&E stain; C and F are H&E stain.
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Tc-99m HL91 偵測腫瘤缺氧：
離體細胞及活體動物之研究
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腫瘤缺氧是造成放射治療及化學治療效果不佳的原因之ㄧ；在治療前，以不具侵入性
缺氧造影檢查評估腫瘤缺氧範圍，進而可以預估病人的預後；因此本研究採用離體細
胞及活體動物實驗，研究 Tc-99m HL91 (HL 91) 是否極具有潛力成為ㄧ個缺氧造影
藥物。將人類肺癌細胞 (A549) 及鼠類肺癌細胞 (LL2) 在缺氧及有氧環境，個別進行
實驗。以 A549 細胞及 LL2 細胞個別接種至小鼠右後大腿，並分成 hydralazine 給
予組及 PBS 給予組，個別進行生物體分佈實驗，核醫造影檢查及自動放射攝影實驗。
細胞結果顯示 HL91 在缺氧環境較有氧環境確實有明顯地放射活性增加。在小鼠活體
實驗，發現 hydralazine 給予組較 PBS 給予組有顯著地 HL91 放射活性增加；在核
醫造影檢查方面，結果亦是如此。至於腫瘤切片的自動放射攝影則證實組織染色切片
為壞死處的放射活性為最低，而壞死處周圍缺氧細胞則有較高放射活性增加的表現。
藉由本實驗結果，證實 HL91 造影的確是可以提供評估腫瘤缺氧範圍及嚴重程度的影
像檢查之運用。
關鍵詞：離體細胞實驗，活體動物實驗，核醫造影檢查，鎝 -99m HL91，腫瘤缺氧
(高雄醫誌 2008;24:461–72)
